問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

List

209Cases

2016-01-01 - 2019-05-31

Phase III

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

  • Condition/Disease

    uncontrolled severe asthma

  • Test Drug

    QAW039

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

許武輝醫師
China Medical University Hospital

Division of Thoracic Medicine

2016-01-01 - 2019-12-31

Phase I

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Condition/Disease

    ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

  • Test Drug

    LDK378

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

2013-07-09 - 2024-01-07

Phase III

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Condition/Disease

    Non small cell lung cancer

  • Test Drug

    LDK378

Participate Sites
7Sites

Terminated7Sites

2012-10-22 - 2014-11-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-11-01 - 2014-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-07-01 - 2012-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-11-16 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting1Sites

Terminated12Sites

2007-12-01 - 2009-01-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-06-25 - 2018-01-09

Phase III

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin ®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

  • Condition/Disease

    NSCLC

  • Test Drug

    PF-06439535

Participate Sites
6Sites

Study ended5Sites

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 16 17 18 19 20 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB